Bailard Inc. Has $1.22 Million Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Bailard Inc. increased its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 1.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,080 shares of the biopharmaceutical company’s stock after purchasing an additional 200 shares during the period. Bailard Inc.’s holdings in Intra-Cellular Therapies were worth $1,223,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Xponance Inc. increased its holdings in shares of Intra-Cellular Therapies by 3.0% during the fourth quarter. Xponance Inc. now owns 5,676 shares of the biopharmaceutical company’s stock worth $407,000 after buying an additional 163 shares in the last quarter. Regal Investment Advisors LLC increased its holdings in shares of Intra-Cellular Therapies by 1.4% in the third quarter. Regal Investment Advisors LLC now owns 13,610 shares of the biopharmaceutical company’s stock valued at $709,000 after purchasing an additional 186 shares in the last quarter. State Board of Administration of Florida Retirement System increased its holdings in shares of Intra-Cellular Therapies by 0.8% in the third quarter. State Board of Administration of Florida Retirement System now owns 26,796 shares of the biopharmaceutical company’s stock valued at $1,396,000 after purchasing an additional 200 shares in the last quarter. Global Retirement Partners LLC boosted its stake in Intra-Cellular Therapies by 13.8% in the third quarter. Global Retirement Partners LLC now owns 1,753 shares of the biopharmaceutical company’s stock valued at $89,000 after acquiring an additional 213 shares during the last quarter. Finally, Signaturefd LLC boosted its stake in Intra-Cellular Therapies by 85.7% in the fourth quarter. Signaturefd LLC now owns 518 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 239 shares during the last quarter. Institutional investors and hedge funds own 92.33% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Suresh K. Durgam sold 6,450 shares of Intra-Cellular Therapies stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $66.56, for a total transaction of $429,312.00. Following the completion of the transaction, the executive vice president now directly owns 16,170 shares in the company, valued at $1,076,275.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Intra-Cellular Therapies news, EVP Suresh K. Durgam sold 6,450 shares of Intra-Cellular Therapies stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $66.56, for a total value of $429,312.00. Following the sale, the executive vice president now owns 16,170 shares of the company’s stock, valued at $1,076,275.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Sharon Mates sold 22,590 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $69.79, for a total transaction of $1,576,556.10. Following the completion of the sale, the chief executive officer now directly owns 1,050,309 shares in the company, valued at approximately $73,301,065.11. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 168,487 shares of company stock worth $11,364,950. 3.40% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ITCI. Robert W. Baird lifted their price target on shares of Intra-Cellular Therapies from $83.00 to $103.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 17th. Canaccord Genuity Group lifted their price target on shares of Intra-Cellular Therapies from $100.00 to $107.00 and gave the stock a “buy” rating in a research report on Tuesday. TD Cowen raised their price objective on shares of Intra-Cellular Therapies from $80.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Royal Bank of Canada restated an “outperform” rating and set a $86.00 price objective on shares of Intra-Cellular Therapies in a report on Wednesday, April 3rd. Finally, Needham & Company LLC raised their price objective on shares of Intra-Cellular Therapies from $82.00 to $90.00 and gave the stock a “buy” rating in a report on Monday. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $90.17.

Intra-Cellular Therapies Trading Up 1.4 %

NASDAQ:ITCI traded up $1.04 on Friday, hitting $73.17. The company had a trading volume of 100,571 shares, compared to its average volume of 932,354. The stock has a market capitalization of $7.08 billion, a price-to-earnings ratio of -49.40 and a beta of 1.02. The firm has a 50 day moving average of $69.38 and a two-hundred day moving average of $64.63. Intra-Cellular Therapies, Inc. has a 52 week low of $45.50 and a 52 week high of $84.89.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.14. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative return on equity of 23.02%. The firm had revenue of $132.10 million during the quarter, compared to the consensus estimate of $135.97 million. During the same quarter last year, the firm earned ($0.45) earnings per share. The company’s revenue for the quarter was up 50.3% on a year-over-year basis. As a group, equities analysts forecast that Intra-Cellular Therapies, Inc. will post -0.62 EPS for the current year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.